ArticleFrontiers in oncology2026
Urachal inflammatory myofibroblastic tumor: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Inflammatory myofibroblastic tumor (IMT) is an uncommon mesenchymal neoplasm. Urachal involvement is exceedingly rare, and evidence regarding its clinical presentation, diagnosis, and management remains limited. Case presentation: We report the case of a 62-year-old female patient who presented with urinary frequency and dysuria for 8 days. Computed tomography (CT) revealed a mass at the junction of the urachus and the anterosuperior wall of the bladder, which was further confirmed by cystoscopy. The patient underwent laparoscopic resection of the urachal mass combined with partial cystectomy. Histopathological examination of the surgical specimen confirmed IMT, and immunohistochemical staining was positive for anaplastic lymphoma kinase (ALK) and vimentin. At the 3-month postoperative follow-up, CT and cystoscopy showed no evidence of local recurrence. Conclusion: UIMT should be considered in the differential diagnosis of urachal or anterosuperior bladder-wall masses. Definitive diagnosis requires integrated histopathological and immunohistochemical assessment, and complete resection with negative margins is the preferred treatment for localized, resectable disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.